Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of...
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggre...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. ...
Market Outlook The multiple myeloma landscape is witnessing successive label...
Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in doublet and trip......
The launch of several novel therapies, as well as multiple label expansions of...
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma...
Coming Soon MARKET OUTLOOK Successive label expansions in the multiple...
Coming Soon MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial rew...
The treatment of multiple myeloma has advanced considerably in recent years...
The treatment of multiple myeloma has advanced considerably in recent years with Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remaining key cornerstones of...
Coming Soon – October 2019 MARKET OUTLOOK Rituximab-based...
Coming Soon – October 2019 MARKET OUTLOOK Rituximab-based chemoimmunotherapy regimens (e.g...
The multiple myeloma therapy market has witnessed considerable advances in...
The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the treatme......
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy...
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to therapy is the primary trea......
MARKET OUTLOOK Myelodysplastic syndromes (MDS) are a heterogeneous...
MARKET OUTLOOK Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stemcell disorders that res......
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Histor......
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. ...
The launch of several novel therapies, as well as multiple label expansions of...
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (...
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over...
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have......
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historic......
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of...
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of...
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s...
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven......
MARKET OUTLOOK. Myelofibrosis is a hematological malignancy characterized by...
MARKET OUTLOOK. Myelofibrosis is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, wea......
Market Outlook The most important clinical distinction in the first-line...
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologo......
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and...
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest sur......
